Jiangsu Kanion Pharmaceutical Co. Ltd. Class ASSE: 600557

Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval Notice

· Issued by Jiangsu Kanion Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval Notice

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment